Puma Biotechnology, Inc. (PBYI) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Puma Biotechnology reported revenue of $228.4M, down 0.9% from $230.5M the year before. Net income was $31.1M (a 13.6% net margin), or $0.61 per diluted share. Gross margin was 74.5% and operating margin was 16.3%. Operating activities generated $41.8M of cash, leaving $41.7M of free cash flow. At fiscal year end, Puma Biotechnology held $216.3M in total assets against $86.0M in total liabilities, including $29.6M of cash and equivalents.
Open the full interactive Puma Biotechnology financials → Quarterly statements, key ratios, valuation history and price charts.
Puma Biotechnology Key Stats
| Share Price | $10.12 |
|---|---|
| Market Cap | $532.3M |
| P/E Ratio | 16.6 |
| Revenue YoY Growth | -0.9% |
| 52-Week Range | $4.73 – $10.29 |
| Shares Outstanding | 50.9 million (basic, 2026 Q2) |
Puma Biotechnology Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $225.1M | $253.2M | $228.0M | $235.6M | $230.5M | $228.4M |
| Cost of Goods Sold | — | $63.7M | $55.1M | $62.7M | $64.4M | $58.2M |
| Gross Profit | — | $189.5M | $172.9M | $173.0M | $166.1M | $170.2M |
| Operating Income | -$30.4M | $1.3M | $23.7M | $32.6M | $31.0M | $37.3M |
| Pre-Tax Income | -$59.8M | -$28.8M | $457,000 | $22.7M | $24.1M | $35.8M |
| Income Tax | $207,000 | $324,000 | $455,000 | $1.1M | -$6.2M | $4.7M |
| Net Income | -$60.0M | -$29.1M | $2,000 | $21.6M | $30.3M | $31.1M |
| Diluted EPS | -$0.38 | -$0.72 | — | $0.45 | $0.62 | $0.61 |
Puma Biotechnology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $54.5M | $75.5M | $44.8M | $56.5M |
| Net Income | $8.8M | $13.4M | -$3.8M | $8.2M |
| Diluted EPS | $0.17 | $0.27 | -$0.07 | $0.16 |
Puma Biotechnology Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $85.3M | $63.1M | $76.2M | $84.6M | $69.2M | $29.6M |
| Current Assets | $146.1M | $140.0M | $134.3M | $156.2M | $147.7M | $162.7M |
| Total Assets | $244.2M | $226.6M | $222.1M | $230.5M | $213.3M | $216.3M |
| Current Liabilities | $114.3M | $109.6M | $77.5M | $99.4M | $96.1M | $81.3M |
| Total Long-Term Debt | $98.3M | $102.0M | $102.0M | $99.7M | $67.0M | $22.7M |
| Total Liabilities | $250.2M | $229.0M | $200.5M | $177.1M | $121.2M | $86.0M |
| Shareholders' Equity | -$6.0M | -$2.4M | $21.6M | $53.4M | $92.1M | $130.3M |
Puma Biotechnology Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $773,000 | $20.6M | -$15.8M | $27.0M | $38.9M | $41.8M |
| Cash From Investing | $23.4M | -$10.9M | $7.1M | -$19.1M | -$20.4M | -$36.2M |
| Cash From Financing | $68,000 | -$31.9M | $12.2M | $0 | -$33.8M | -$45.2M |
| Free Cash Flow | $800,000 | $20.7M | -$15.8M | $26.9M | $38.8M | $41.7M |
Figures from Puma Biotechnology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Puma Biotechnology financials page for every line item.
Puma Biotechnology Company Profile
| Ticker | PBYI |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Los Angeles, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer, smaller reporting company |
| SEC CIK | 0001401667 |
Frequently Asked Questions
What was Puma Biotechnology's revenue in fiscal 2025?
Puma Biotechnology (PBYI) reported revenue of $228.4M for fiscal 2025.
What is Puma Biotechnology's annual revenue history?
Puma Biotechnology's annual revenue by fiscal year: 2020: $225.1M; 2021: $253.2M; 2022: $228.0M; 2023: $235.6M; 2024: $230.5M; 2025: $228.4M.
What was Puma Biotechnology's net income in fiscal 2025?
Puma Biotechnology reported net income of $31.1M for fiscal 2025.
What was Puma Biotechnology's earnings per share (EPS) in fiscal 2025?
Puma Biotechnology's diluted EPS was $0.61 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Puma Biotechnology generate in fiscal 2025?
Puma Biotechnology generated $41.7M of free cash flow in fiscal 2025.
What was Puma Biotechnology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Puma Biotechnology reported revenue of $56.5M.
How much debt does Puma Biotechnology have?
Puma Biotechnology reported $22.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Puma Biotechnology are outstanding?
Puma Biotechnology reported a weighted average of 50.9 million basic shares outstanding in 2026 Q2.
What is Puma Biotechnology's market cap?
Based on its latest closing price, Puma Biotechnology (PBYI) has a market capitalization of about $532.3M.
When does Puma Biotechnology's fiscal year end?
Puma Biotechnology's fiscal year end, as registered with the SEC, is December 31.
Where is Puma Biotechnology headquartered?
Puma Biotechnology lists its business address in Los Angeles, California in its SEC filings.